Name | Title | Contact Details |
---|
Virobay is focused on the development and commercialization of novel drugs through the utilization of small molecule inhibitors of cysteine proteases, a diverse class of enzyme proteases, for a variety of conditions, including neuropathic pain, autoimmune diseases and fibrosis. The foundation of Virobay's proprietary cathepsin platform and the Virobay management team were spun-out from Celera Genomics, which was then a leader in cathepsin research. Virobay's clinical pipeline currently includes product candidates in neuropathic pain, dermatology, autoimmune disease and fibrosis.
Immusoft Corporation (immusoft.com) is a pre-clinical gene therapy company based in Seattle, Wash. Its mission is to treat diseases using its breakthrough technology platform called Immune System Programming.
Replimune is creating a new class of oncolytic immunotherapy designed to ignite a powerful immune response to treat cancer and vaccinate against future relapse. Replimune`s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response. Replimune is pioneering the development of novel tumor-directed oncolytic immunotherapies. We imagine a world where cancer is a curable disease.
Ventana Clinical Research Corp is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cerber-Net is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.